Literature DB >> 668195

Evaluation of isoniazid-associated hepatitis by immunological tests.

R J Warrington, K S Tse, B A Gorski, R Schwenk, A H Sehon.   

Abstract

In a retrospective study of patients developing hepatitis or persistent serum glutamic oxaloacetic transaminase (SGOT) elevations while receiving isoniazid, it was found that the lymphocyte transformation test (LTT) was positive in nineteen cases (95%) in response to stimulation by isoniazid, isonicotinic acid and conjugates of these compounds with human serum albumin. However, no significant amount of antibody against isoniazid was detected in the sera of these patients by a sensitive radioimmunoassay. By contrast, no positive LTT was seen in normal controls or in patients receiving isoniazid without evidence of liver damage, while in patients with transient SGOT abnormalities, the LTT was positive only at the time of liver dysfunction. There was no correlation between the degree of lymphocyte transformation and the severity of liver damage. However, there were differences in the patterns of response to the four stimulatory preparations used. Thus patients with overt hepatitis most frequently responded to isoniazid, while individuals with only SGOT abnormalities showed stimulation in the LTT more often with a conjugate of isonicotinic acid and human serum albumin. It appears, therefore, that the presence of isoniazid-induced liver damage is associated with the presence of cellular hypersensitivity to the drug. The differences in lymphocyte reactivity in the two groups might indicate a potential means of predicting which individuals are at increased risk of developing overt hepatitis when exhibiting evidence of minor liver dysfunction while receiving isoniazid.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 668195      PMCID: PMC1541309     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  The competing risks of tuberculosis and hepatitis for adult tuberculin reactors.

Authors:  G W Comstock; P Q Edwards
Journal:  Am Rev Respir Dis       Date:  1975-05

2.  Toxic hepatic necrosis (hepatitis) due to isoniazid: report of a case with cirrhosis and death due to hemorrhage from esophageal varices.

Authors:  A D MERRITT; B F FETTER
Journal:  Ann Intern Med       Date:  1959-03       Impact factor: 25.391

3.  Icterus and febrile reactions in response to isonicotinic acid hydrazine; report of two cases and review of the literature.

Authors:  E HABER; R K OSBORNE
Journal:  N Engl J Med       Date:  1959-02-26       Impact factor: 91.245

4.  Isoniazid hepatitis.

Authors:  W C Maddrey; J K Boitnott
Journal:  Ann Intern Med       Date:  1973-07       Impact factor: 25.391

5.  The effect of isoniazid on transaminase levels.

Authors:  W C Bailey; H Weill; T A DeRouen; M M Ziskind; H A Jackson
Journal:  Ann Intern Med       Date:  1974-08       Impact factor: 25.391

6.  Disturbed hepatic function during isoniazid chemoprophylaxis. Monitoring the hepatic function of 427 hospital employees receiving isoniazid chemoprophylaxis for tuberculosis.

Authors:  W C Bailey; S L Taylor; H E Dascomb; H B Greenberg; M M Ziskind
Journal:  Am Rev Respir Dis       Date:  1973-04

7.  Failure to demonstrate transformation of lymphocytes of patients with isoniazid-associated hepatitis.

Authors:  J T Dove; S D Chaparas; S R Hedrick
Journal:  Am Rev Respir Dis       Date:  1972-09

8.  Liver damage and isoniazid allergy.

Authors:  E S Assem; N Ndoping; H Nicholson; J R Wade
Journal:  Clin Exp Immunol       Date:  1969-10       Impact factor: 4.330

9.  Studies on the metabolic basis for the genetically determined capacities for isoniazid inactivation in man.

Authors:  J H Peters; K S Miller; P Brown
Journal:  J Pharmacol Exp Ther       Date:  1965-11       Impact factor: 4.030

10.  Immunological studies in patients with chronic active hepatitis. Cytotoxic activity of lymphocytes to autochthonous liver cells grown in tissue culture.

Authors:  F Paronetto; S Vernace
Journal:  Clin Exp Immunol       Date:  1975-01       Impact factor: 4.330

View more
  13 in total

1.  Diallyl trisulfide protects the liver against hepatotoxicity induced by isoniazid and rifampin in mice by reducing oxidative stress and activating Kupffer cells.

Authors:  Yilin Yang; Lulu Jiang; Shuo Wang; Tao Zeng; Keqin Xie
Journal:  Toxicol Res (Camb)       Date:  2016-04-01       Impact factor: 3.524

Review 2.  Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models.

Authors:  Richard J Weaver; Eric A Blomme; Amy E Chadwick; Ian M Copple; Helga H J Gerets; Christopher E Goldring; Andre Guillouzo; Philip G Hewitt; Magnus Ingelman-Sundberg; Klaus Gjervig Jensen; Satu Juhila; Ursula Klingmüller; Gilles Labbe; Michael J Liguori; Cerys A Lovatt; Paul Morgan; Dean J Naisbitt; Raymond H H Pieters; Jan Snoeys; Bob van de Water; Dominic P Williams; B Kevin Park
Journal:  Nat Rev Drug Discov       Date:  2019-11-20       Impact factor: 84.694

3.  [Immune reactions in pseudo-lupus-syndrome. A long-term study (author's transl)].

Authors:  P Schuff-Werner; P A Berg
Journal:  Klin Wochenschr       Date:  1980-09-15

4.  Lack of liver injury in Wistar rats treated with the combination of isoniazid and rifampicin.

Authors:  Imir G Metushi; Jack Uetrecht
Journal:  Mol Cell Biochem       Date:  2013-10-23       Impact factor: 3.396

5.  Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response.

Authors:  Jessica Whritenour; Mira Ko; Qing Zong; Jianying Wang; Karrie Tartaro; Patricia Schneider; Ellen Olson; Maria Van Volkenburg; Jose Serrano; Paul Hayashi; Robert Fontana; Naga Chalasani; Herbert L Bonkovsky
Journal:  J Immunotoxicol       Date:  2017-12       Impact factor: 3.000

6.  Lymphocyte-mediated cytotoxicity in isoniazid-associated hepatitis.

Authors:  R J Warrington; S L Olivier
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

7.  Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure.

Authors:  Imir G Metushi; Corron Sanders; William M Lee; Jack Uetrecht
Journal:  Hepatology       Date:  2014-01-27       Impact factor: 17.425

Review 8.  Mechanism of isoniazid-induced hepatotoxicity: then and now.

Authors:  Imir Metushi; Jack Uetrecht; Elizabeth Phillips
Journal:  Br J Clin Pharmacol       Date:  2016-02-25       Impact factor: 4.335

9.  The effect of ageing on isoniazid pharmacokinetics and hepatotoxicity in Fischer 344 rats.

Authors:  John Mach; Aniko Huizer-Pajkos; Sarah J Mitchell; Catriona McKenzie; Leo Phillips; Alice Kane; Brett Jones; Rafael de Cabo; Victoria Cogger; David G Le Couteur; Sarah N Hilmer
Journal:  Fundam Clin Pharmacol       Date:  2015-11-09       Impact factor: 2.748

10.  miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model.

Authors:  Merrie Mosedale; J Scott Eaddy; O Joseph Trask; Natalie S Holman; Kristina K Wolf; Edward LeCluyse; Brenton R Ware; Salman R Khetani; Jingtao Lu; William J Brock; Sharin E Roth; Paul B Watkins
Journal:  Toxicol Sci       Date:  2018-01-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.